Cytek Biosciences (CTKB) Cash & Equivalents (2020 - 2026)

Cytek Biosciences' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $65.7 million for Q1 2026.

• Quarterly Cash & Equivalents fell 31.06% year-over-year to $65.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $65.7 million (down 31.06% YoY) and the FY2025 annual result came in at $90.9 million, down 7.97% from the prior year.
• Cash & Equivalents was $65.7 million for Q1 2026 at Cytek Biosciences, down from $90.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $362.5 million in Q1 2022 and bottomed at $65.7 million in Q1 2026.
• A 5-year average of $173.4 million and a median of $162.3 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents jumped 112.28% — and 2023, when it slumped 64.28%.
• Cytek Biosciences' Cash & Equivalents stood at $296.6 million in 2022, then tumbled by 43.59% to $167.3 million in 2023, then plunged by 40.99% to $98.7 million in 2024, then decreased by 7.97% to $90.9 million in 2025, then decreased by 27.69% to $65.7 million in 2026.
• Business Quant data shows CTKB's Cash & Equivalents at $65.7 million in Q1 2026, $90.9 million in Q4 2025, and $93.3 million in Q3 2025.